118 related articles for article (PubMed ID: 14654560)
1. Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro.
Kutko MC; Glick RD; Butler LM; Coffey DC; Rifkind RA; Marks PA; Richon VM; LaQuaglia MP
Clin Cancer Res; 2003 Nov; 9(15):5749-55. PubMed ID: 14654560
[TBL] [Abstract][Full Text] [Related]
2. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
Butler LM; Agus DB; Scher HI; Higgins B; Rose A; Cordon-Cardo C; Thaler HT; Rifkind RA; Marks PA; Richon VM
Cancer Res; 2000 Sep; 60(18):5165-70. PubMed ID: 11016644
[TBL] [Abstract][Full Text] [Related]
3. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
[TBL] [Abstract][Full Text] [Related]
5. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
6. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
Marchion DC; Bicaku E; Daud AI; Richon V; Sullivan DM; Munster PN
J Cell Biochem; 2004 May; 92(2):223-37. PubMed ID: 15108350
[TBL] [Abstract][Full Text] [Related]
7. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
Munster PN; Troso-Sandoval T; Rosen N; Rifkind R; Marks PA; Richon VM
Cancer Res; 2001 Dec; 61(23):8492-7. PubMed ID: 11731433
[TBL] [Abstract][Full Text] [Related]
8. [Regulation of histone acetylation on the expression of cell cycle-associated genes in human colon cancer cell lines].
Chen YX; Fang JY; Lu J; Qiu DK
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):312-7. PubMed ID: 15059516
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase.
Butler LM; Webb Y; Agus DB; Higgins B; Tolentino TR; Kutko MC; LaQuaglia MP; Drobnjak M; Cordon-Cardo C; Scher HI; Breslow R; Richon VM; Rifkind RA; Marks PA
Clin Cancer Res; 2001 Apr; 7(4):962-70. PubMed ID: 11309347
[TBL] [Abstract][Full Text] [Related]
11. Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status.
Folkvord S; Ree AH; Furre T; Halvorsen T; Flatmark K
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):546-52. PubMed ID: 19427556
[TBL] [Abstract][Full Text] [Related]
12. Suberoylanilide hydroxamic acid enhances gap junctional intercellular communication via acetylation of histone containing connexin 43 gene locus.
Ogawa T; Hayashi T; Tokunou M; Nakachi K; Trosko JE; Chang CC; Yorioka N
Cancer Res; 2005 Nov; 65(21):9771-8. PubMed ID: 16266998
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.
Sakajiri S; Kumagai T; Kawamata N; Saitoh T; Said JW; Koeffler HP
Exp Hematol; 2005 Jan; 33(1):53-61. PubMed ID: 15661398
[TBL] [Abstract][Full Text] [Related]
14. Effect of trichostatin A, a histone deacetylase inhibitor, on glioma proliferation in vitro by inducing cell cycle arrest and apoptosis.
Wetzel M; Premkumar DR; Arnold B; Pollack IF
J Neurosurg; 2005 Dec; 103(6 Suppl):549-56. PubMed ID: 16383255
[TBL] [Abstract][Full Text] [Related]
15. Novel histone deacetylase inhibitors in the treatment of thyroid cancer.
Mitsiades CS; Poulaki V; McMullan C; Negri J; Fanourakis G; Goudopoulou A; Richon VM; Marks PA; Mitsiades N
Clin Cancer Res; 2005 May; 11(10):3958-65. PubMed ID: 15897598
[TBL] [Abstract][Full Text] [Related]
16. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMullan C; Miller JW; Marks PA; Mitsiades N
Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4072-9. PubMed ID: 19387079
[TBL] [Abstract][Full Text] [Related]
17. SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway.
Hrzenjak A; Kremser ML; Strohmeier B; Moinfar F; Zatloukal K; Denk H
J Pathol; 2008 Dec; 216(4):495-504. PubMed ID: 18850582
[TBL] [Abstract][Full Text] [Related]
18. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.
Sonnemann J; Kumar KS; Heesch S; Müller C; Hartwig C; Maass M; Bader P; Beck JF
Int J Oncol; 2006 Mar; 28(3):755-66. PubMed ID: 16465382
[TBL] [Abstract][Full Text] [Related]
20. Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents.
Dong G; Wang L; Wang CY; Yang T; Kumar MV; Dong Z
J Pharmacol Exp Ther; 2008 Jun; 325(3):978-84. PubMed ID: 18310471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
